Acute haemodynamic effects of endralazine in patients with coronary artery disease and stable angina pectoris.
The acute haemodynamic effects of endralazine, a new hydralazine-like vasodilating agent, were studied in 6 patients with stable angina pectoris and proven coronary artery disease. Twenty minutes after intravenous administration of 5 mg endralazine heart rate and cardiac index increase, while mean arterial blood pressure and total systemic resistance were significantly reduced. Three patients developed symptoms of typical angina pectoris 15 to 20 minutes after drug administration, probably caused by reflex tachycardia. We conclude that intravenous administration of endralazine causes marked haemodynamic effects for the drug is a potent arterial vasodilator, but it may precipitate anginal chest pain in patients with coronary artery disease.
D000787:Angina Pectoris / Q000503:physiopathology*; D003327:Coronary Disease / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D011724:Pyridazines; D014665:Vasodilator Agents; C014926:BQ 22-708